|1.||Camilleri, M: 2 articles (02/2014 - 10/2007)|
|2.||Kim, Sang Woo: 2 articles (04/2013 - 03/2004)|
|3.||Cho, Yu Kyung: 2 articles (04/2013 - 03/2004)|
|4.||Lee, In Seok: 2 articles (04/2013 - 03/2004)|
|5.||Choi, Myung-Gyu: 2 articles (04/2013 - 03/2004)|
|6.||Crowell, Michael D: 2 articles (12/2009 - 09/2004)|
|7.||Lundell, Lars: 2 articles (10/2003 - 01/2002)|
|8.||Finizia, Caterina: 2 articles (10/2003 - 01/2002)|
|9.||Ruth, Magnus: 2 articles (10/2003 - 01/2002)|
|10.||Cange, Lars: 2 articles (10/2003 - 01/2002)|
02/01/2014 - "Demonstration of efficacy on patient-important outcomes and a favourable safety profile support the continued use and development of highly selective 5-HT4 agonists in the treatment of chronic constipation."
02/01/2014 - "Highly selective 5-HT4 agonists have been suggested for the treatment of chronic constipation (CC). "
01/01/2010 - "We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of non-drug interventions, bulk-forming laxatives, faecal softeners, stimulant laxatives, osmotic laxatives, prostaglandin derivatives, and 5-HT4 agonists in adults with idiopathic chronic constipation? "
05/01/2005 - "5-HT4 agonists are prokinetic and relieve discomfort and constipation in IBS-C and chronic constipation. "
01/01/2001 - "In constipation 5-HT4 agonists have lead to specific activation of motor events responsible for gut transport. "
|2.||Irritable Bowel Syndrome (Syndrome, Irritable Bowel)
10/01/2007 - "We hypothesized that the combination of 5-HT4 agonist and non-selective opioid antagonist enhances intestinal transit more than either treatment alone in female constipation-predominant irritable bowel syndrome (C-IBS) patients. "
07/01/2009 - "Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis."
12/01/2006 - "Useful information has paradoxically come from the side effects of the 5-HT3 antagonists and 5-HT4 agonists used in treatment of irritable bowel syndrome patients."
08/01/2006 - "Bloating in irritable bowel syndrome (IBS) may result from impaired intestinal gas transit and is reduced by the 5-HT4 agonist tegaserod. "
08/01/2002 - "Tegaserod, a 5-HT4 agonist, is useful for women with irritable bowel syndrome who are constipated. "
|3.||Gastroesophageal Reflux (GERD)
04/01/2015 - "Randomised clinical trial: the 5-HT4 agonist revexepride in patients with gastro-oesophageal reflux disease who have persistent symptoms despite PPI therapy."
04/01/2007 - "Significant stimulatory impact of 5-HT4 agonist on several salivary protective factors as well as esophageal EGF secretion may have esophagoprotective implications in patients with GERD and may help to address new therapies in the future."
04/01/2013 - "We evaluated the effect of mosapride, a 5-HT4 agonist, and PPI cotherapy in patients with GERD on esophageal motility using high-resolution manometry (HRM). "
01/01/2002 - "To evaluate the efficiency by which the 5-HT4 agonist cisapride affects important motor functions involved in the control of gastro-oesophageal reflux. "
10/01/2003 - "To evaluate the efficiency of the 5-HT4 agonist and 5-HT3 antagonist mosapride, as compared with cisapride, on oesophageal acid reflux variables and oesophageal motor function in patients with chronic gastro-oesophageal reflux disease (GORD). "
|4.||Alzheimer Disease (Alzheimer's Disease)
01/01/2007 - "Activation of 5-HT4 receptors has been shown to improve memory processes in preclinical cognition models, suggesting potential utility of 5-HT4 agonists for the symptomatic treatment of Alzheimer's disease (AD). "
12/16/2008 - "5-HT4 agonists are currently being developed for the treatment of Alzheimer's disease and have previously been demonstrated to improve cognitive performance in a variety of tests but none that specifically test attention. "
05/01/2004 - "With respect to neurodegenerative disorders, it is suggested that 5-HT4 agonists may represent a new avenue for the treatment of Alzheimer's disease. "
|5.||Respiratory Insufficiency (Respiratory Failure)
09/01/2005 - "Our results show that, with mosapride, opioid-induced respiratory depression cannot be prevented, and because other 5-HT4 agonists are not currently available for clinical use, a cure for opioid-induced respiratory depression as promised by the previous successful experiments in laboratory animals is not yet available in clinical practice."
09/01/2005 - "On the basis of experiments in rats, serotonin 4 receptor (5-hydroxytryptamine 4 [5-HT4]) agonists have been proposed as a novel therapeutic strategy for the selective treatment of respiratory depression caused by opioids while leaving analgesic effects unaffected. "
|2.||Serotonin 5-HT3 Receptor Antagonists
|5.||Epidermal Growth Factor (EGF)
|8.||Serotonin (5 Hydroxytryptamine)
|9.||Adrenocorticotropic Hormone (ACTH)
|10.||5-HT4 Serotonin Receptors
|2.||Drug Therapy (Chemotherapy)